| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.8 |